


Patient Card



IMPORTANT Information for Patients

Carry this card with you at all times to inform healthcare professionals that you are receiving treatment with nivolumab, or nivolumab in combination with YERVOY® (ipilimumab).



Nivolumab can increase the risk of serious or even life-threatening side effects, which may affect different parts of the body. If you have any signs or symptoms, tell your doctor right away. This includes any possible side effects not included in this card or in the OPDIVO (nivolumab) Consumer Medicine Information.

POSSIBLE SIDE EFFECTS¹

	Chest (heart and lungs)	Breathing difficulties, cough, wheeze, chest pain, irregular heartbeat, palpitations (increased awareness of your heartbeat)
	Gut (stomach and bowels)	Diarrhoea (watery, loose or soft stools), blood or mucous in stools, dark-coloured stools, pain or tenderness in your stomach or abdominal area
	Liver	Eye or skin yellowing (jaundice), pain on the right side of your stomach area
	Kidneys	Change in amount and/or frequency of urine
	Hormone-producing glands (including diabetes)	Headaches, blurry or double vision, fatigue (tiredness), weight changes, behavioural changes (e.g. lower sex drive, irritability or forgetfulness), excessive thirst, increased appetite with weight loss, weakness, drowsiness, depression, feeling unwell, change in amount and/or frequency of urine
	Skin	Rash, itching, blisters and/or peeling of the skin (possibly fatal), ulcers, dry skin, skin nodules
	Other	Weakness, fatigue (tiredness), decreased appetite, nausea, vomiting, tingling or numbness in arms and legs, difficulty walking, fever, swollen lymph nodes, headache, seizures, stiff neck, confusion, drowsiness, muscle pain, stiffness, dark urine, eye pain or redness, blurry vision, or other vision problems

My Doctor's Contact Information

(who prescribed nivolumab, or nivolumab in combination with ipilimumab)

Name of Doctor: _____

Office Phone: _____

After-Hours Phone: _____

My Contact Information

My Name: _____

My Phone Number: _____

Emergency Contact (name and phone number): _____

IMPORTANT

- Tell your doctor of any previous medical conditions, including if you have had a stem cell transplant that uses donor stem cells (allogeneic).
- Early assessment and management of side effects by your doctor reduces the likelihood that treatment with nivolumab, or nivolumab in combination with ipilimumab, will need to be temporarily or permanently stopped.
- Signs and symptoms that may appear mild can quickly worsen if left untreated.
- **DO NOT** try to treat these symptoms yourself.
- Signs and symptoms can appear during treatment or may be delayed and may occur weeks to months after your last injection.

For more information, read the OPDIVO (nivolumab) Consumer Medicine Information (www.medsafe.govt.nz/consumers/cmi/o/opdivo.pdf) or call BMS Medical Information on **0800 167 567**.

IMPORTANT Information for Healthcare Professionals

- This patient is treated with nivolumab, or nivolumab in combination with ipilimumab.
- Immune-related adverse reactions may appear at any time during treatment or months after its discontinuation.
- Early diagnosis and appropriate management are essential to minimise life-threatening complications.
- Consultation with an oncologist or other medical specialist may be helpful for management of organ-specific immune-related adverse reactions.
- Healthcare professionals should refer to the OPDIVO (nivolumab) Data Sheet (www.medsafe.govt.nz/profs/datasheet/o/opdivoinf.pdf) or contact BMS Medical Information on **0800 167 567** or medinfo.australia@bms.com for more information.

The healthcare professional treating this patient with nivolumab or nivolumab in combination with ipilimumab, should complete the 'My Doctor's Contact Information' section of this Patient Card.

OPDIVO (nivolumab 10mg/mL) is a prescription medicine used: As monotherapy (on its own) for: advanced melanoma, kidney cancer, certain lung cancers, head and neck cancer, bladder cancer, blood cancer, liver cancer, and food pipe cancer. Also after surgical removal of melanoma, food pipe cancer, gastroesophageal junction cancer, and bladder cancer. Combined with YERVOY (ipilimumab 5mg/mL) for: advanced melanoma, advanced kidney cancer, and lung lining cancer (mesothelioma). Combined with YERVOY and chemotherapy for: certain lung cancers. Combined with chemotherapy for: lung cancer (before surgery), stomach cancer, gastroesophageal junction cancer, food pipe cancer, and bladder cancer. Combined with cabozantinib for: advanced kidney cancer.

Do not use OPDIVO or YERVOY if you are allergic (hypersensitive) to nivolumab or ipilimumab, or to any of the other ingredients of OPDIVO or YERVOY. If you are not sure talk to your doctor. Discuss the risks and benefits of OPDIVO or OPDIVO with YERVOY with your doctor, who can advise if these treatments are right for you and provide ongoing support and guidance. Tell your doctor about your current or past medical conditions, any auto-immune diseases, and other medicines you are taking. Use OPDIVO or OPDIVO in combination with YERVOY strictly as directed. OPDIVO is a funded medicine for advanced melanoma and advanced kidney cancer, and OPDIVO with YERVOY is funded for metastatic kidney cancer—restrictions apply. A prescription charge and normal Doctor's fees may apply. OPDIVO and YERVOY are not funded by Pharmac for the treatment of other cancers listed above. Ask your health professional about the cost of the medicine and any other medical fees that may apply.

Reference: 1. OPDIVO® (nivolumab) Data Sheet.

© 2025 Bristol-Myers Squibb Company. OPDIVO® and YERVOY® are registered trademarks of Bristol-Myers Squibb Company. Bristol-Myers Squibb (NZ) Limited, Auckland, New Zealand.

BMS Medical Information: 0800 167 567 (toll free) or medinfo.australia@bms.com. 1506-NZ-2500015. Side effects should be reported to BMS Medical Information on 0800 167 567. TAPS: MR12347. Date of preparation: September 2025. BRISOY0010.